Invesco Ltd. Concert Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.27 - $7.2 $1.01 Million - $1.71 Million	237,277 New	237,277 $1.59 Million
Q1 2021 May 17, 2021	SELL	$4.86 - $13.07 $79,699 - $214,334	-16,399 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.48 - $12.84 $28,790 - $38,995	3,037 Added 22.73%	16,399 $207,000
Q3 2020 Nov 16, 2020	SELL	$8.67 - $10.82 $507,073 - $632,818	-58,486 Reduced 81.4%	13,362 $131,000
Q2 2020 Aug 14, 2020	SELL	$7.8 - $11.52 $25,217 - $37,244	-3,233 Reduced 4.31%	71,848 $714,000
Q1 2020 May 15, 2020	BUY	$5.98 - $13.09 $348,693 - $763,277	58,310 Added 347.68%	75,081 $664,000
Q4 2019 Feb 14, 2020	SELL	$5.71 - $9.22 $6,292 - $10,160	-1,102 Reduced 6.17%	16,771 $155,000
Q3 2019 Nov 14, 2019	SELL	$5.88 - $12.35 $4,092 - $8,595	-696 Reduced 3.75%	17,873 $105,000
Q2 2019 Aug 14, 2019	SELL	$9.44 - $13.12 $52,307 - $72,697	-5,541 Reduced 22.98%	18,569 $223,000
Q1 2019 May 15, 2019	BUY	$12.07 - $17.54 $291,007 - $422,889	24,110 New	24,110 $291,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.